JRoon, don't presume to know what Always is referring to, but my guess would be the discussion and exwannabe's latest post highlighting how the system (script writing, insurance, pharmacies) is conspiring or at least enabled to be gamed to screw Vascepa with brand scripts getting substituted by generics in clear violation of patents but with nothing seemingly being able to be done. A runaway train.

Some similarities and some not when comparison to LaJolla.  One thing that is similar is they had a drug that in no way met sales expectations as is the case here.  But I assume that you don't mean that being "Tang'd" is necessarily bad unless someone has a high cost basis here.  

Not sure if you saw today that Powell of the Fed Reserve developed a backbone and is saying he won't step down if asked. 

Well for one they just reported earnings and not only have they gotten into the black, but revenues are increasing, unlike Amarin.  Secondly, their approved drug has no generic competition, again, unlike Amarin.  

Yes, hope it is not a misread or BS leak of FDA news and this craters after rejection.  Will hope for good news but always bracing for bad.  

So crazy.  How can a stock be up over 13% one day and down 5% in premarket the next on no news!

Announced a strategic restructuring to "focus on Lupkynis and AUR200".  What the hell were they focusing on before?

To me it sounds like they are clearing the decks to be acquired. 

Well touching $8 in premarket this morning.  Announced earnings.  $.10 per share profit.  Laying off 45% of employees.  Probably none of the fat cats. 

Denisk, Kiwi, thanks. To answer Denisk, I have had this position for 2 years with a cost basis in the 80's. It is in my dividend portfolio for income. Seems a reaction to the election - they are a REIT that caters to the MJ market. Revenue might be light comparatively but over a 50% net profit margin. Waiting for 3Q earnings that was supposed to be released today after market, but company website indicates ER tomorrow. Kiwi, yet ARDX and RZLT did well today. I have not reduced any of those positions. Good luck to us all.

Well I finally have one that is killing me more than AMRN.  IIPR.  Man

Not sure if this has been discussed or mentioned but in the press release for the Investor Conference there was this line:
"Throughout the event, there will be no live interaction with audience participants". Fine. However, in the earnings call, Berg said the following (my question is about the part that I highlighted in bold as to what that is referring to. Will we have a live discussion with prescribers and partners?):

So, this thing looks like it wants to move higher. Question is, will it stop at 9.5 or will we see double digits?

Ram, JRoon, thanks for the responses. Even though when I first bought into Amarin (pre-Marine) I didn't think I would be holding more than 10 years later, I am somehow guessing we won't see a share BB ten years from now. Now, that could easily be because I will be dead by then!

How long is that share buyback approval for?

Investors don’t seem to be too spooked yet considering no pr from the co yet.

It would be nice. Deathly afraid of RS so anything that can get us up.

So no news today I see. Were you saying they can wait another 4 days?

Final rule from CMS regarding ESRD payments:

https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f

What would Denner get out of the deal? He can buy shares at 58 cents currently?

Wonder if they know that without the milestone payments that next qtr will show a larger drawdown in cash?

I was expecting to see Amarin on the list, but I understand the point. Unfortunately that list has not been very successful - so far - only 2 stocks mentioned are slightly higher than date of publication. No question that sometimes investing in negative EV stocks can be rewarding, but it is fairly dangerous, depending on the circumstances of the negative EV. A company can turn around if the market's view of it changes as its business improves, but it can also go bankrupt if the market was original correct in the assessment. Thanks for the link.

I believe (could be wrong and welcome correction) but I believe the discussion was related to API before it got encapsulated.

Good question Sleven and I haven't quickly been able to get the answer. For those that are unaware, EPA does not freeze until the temp gets down to -54 degrees C. I did find one place that says that they store it at -20d C.
https://www.caymanchem.com/product/90110/eicosapentaenoic-acid

Thanks Kiwi. If by Friday you mean yesterday, then we didn’t get a negative PR. Hoping for something +ve early this coming week.

What gives you so much confidence of a win against CMS?

Well not anymore. All afterhour gains evaporated.

Yep. Is our resident Dr. Ralph Cramden?

Thanks Zip. Is the “new” cost basis for those transferred shares the value as of the date of the RMD transfer or still the original cost basis?

Market seems to like earnings released today. Good increases in sales of the 2 drugs. Revenue increase but earnings decrease. Increased SGA costs. Bugs the heck out of me when they don’t control spending better but as long as sp advances.

Thank you for sharing North.

Capt., not to impose on you but I will have to start RMDs next year and are you saying that you took the RMD in stock and deposited into a tax account? Can you do an RMD with a combination of stock and cash? TIA if you desire to disclose.

I would defer to those more knowledgeable in this area, but this AI description indicates that an AG can sometimes be used in settlements in infringement cases since you mention a possible settlement.

I think for an appreciable effect however whatever arrangement would need to incorporate the other Generic cos besides Hikma. It does unfortunately sound more like for patent litigation rather than infringement but I did see something yesterday that mentioned an AG being using in an infringement litigation. FWIW:

"AI Overview

Authorized generics (AGs) can be a source of litigation and settlement because they can impact the generic drug industry and the Hatch-Waxman Act :

Competition
AGs can increase competition for generic drugs during the 180-day exclusivity period granted to the first generic by the Hatch-Waxman Act. This can make it difficult for generic companies to recover litigation costs and reduce their potential reward for challenging patents.

Hatch-Waxman Act
AGs don't have to follow the Hatch-Waxman Act's 180-day exclusivity period, which could threaten the generic industry.

Settlement
A brand company may choose to settle patent litigation with a generic company by launching an AG. Settlements can be economically rational if the net present value of the settlement is greater than the cost of litigation for both parties. "

Actually your scenario is very upbeat and I would be thrilled if by this time next year ex-US sales were equal to US sales - assuming it is not because US sales dropped by much more than 5%.

I understand that logic but I don't know if that impacts the guilt or innocence of the offending party. One could argue that the illegal infringement was so devastating to Amarin that introducing an AG was the company trying everything it could to survive. If everything in the courts didn't move at such a glacial pace.

So we should see a more significant drop in cash next qtr right? Assuming no further payments coming in. Gotta hope for no more PBMs dropping brand V and on a hopeful note maybe Amarin can negotiate their way back onto the CvS Caremark formulary in the New Year.

I don’t know the answer but management mentions they are looking and getting ready at every PR. Maybe we get a little more info about an AG at the Investors Conference

You are correct with one caveat. Revenue went from 55m to 47m to 42m in qtr 1,2,3. The drops of course related to drops in US sales. We have to hope that no more carriers/PBMs use the CVS example to drop brand V in the future. If there is no more/much erosion then I think we are on a path (albeit a snail's pace) to a comeback.

“-- Company Remains Committed to Maintaining Public Listing –“

That worries me a little. Everyone knows why.

Obviously water under the bridge and just daydreaming, but was thinking about JL's "fast nickels over slow dimes" motto, and wondered how our trajectory would have changed if Amarin had been able to snag Germany early and right off the bat. It would have obviously required a more aggressive discount on pricing but.... fast nickels over slow dimes....

The company has been bringing down SGA expenses - albeit imho they waited too long to do so. Checked back and Q3 for 2022 the SGA was 58.7 million and the last qtr 3 months ago it was down to 38 million. The previous qtr it was 39.8 million so it could be that they are bumping up against whatever minimum is needed to operate considering they are trying to spread out worldwide. Thought just crossed my mind, that they should have let North invest their cash for them and now we would be sitting on a goldmine!

Good point JRoon.